On July 13, Alebund Pharmaceuticals-B fell 7.56% in regular trading, trading at 27.42 HKD/share, with turnover of HKD 2.1965 million.

The stock has experienced sharp volatility since listing on June 29 at an IPO price of 22.6 HKD. After surging over 103% on its debut, the stock underwent multiple rounds of rapid gains and declines. A previous disclosure that GIC and LAV collectively increased holdings by over 1.32 million shares (involving approximately HKD 59 million) drove a single-day gain exceeding 10% on July 8, but the stock has since retreated consecutively. The current price represents a pullback of over 40% from the first-day high of 46.82 HKD.

The company is an innovative pharmaceutical enterprise focused on kidney diseases. Its core product AP301 has entered the NDA sprint phase, approximately 12 to 24 months from commercialization. The low-volume decline indicates that selling pressure has not yet been fully released, as short-term profit-taking continues to weigh on the newly listed stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)